Lenze Ulrich, Pohlig Florian, Seitz Sebastian, Ern Christina, Milz Stefan, Docheva Denitsa, Schieker Matthias
Laboratory of Experimental Surgery and Regenerative Medicine, Department of Surgery, University of Munich (LMU), Munich, Germany.
BMC Musculoskelet Disord. 2014 Oct 16;15:350. doi: 10.1186/1471-2474-15-350.
Tissue engineering approaches for reconstruction of large bone defects are still technically immature, especially in regard to sufficient blood supply. Therefore, the aim of the present study was to investigate the influence of osteogenic stimulation and treatment with VEGF on new bone formation and neovascularization in hMSC-loaded cancellous bone scaffolds in vivo.
Cubic scaffolds were seeded with hMSC and either cultured in stem cell medium or osteogenic stimulation medium. One osteogenically stimulated group was additionally treated with 0.8 μg VEGF prior to subcutaneous implantation in athymic mice. After 2 and 12 weeks in vivo, constructs and selected organs were harvested for histological and molecular analysis.
Histological analysis revealed similar vascularization of the constructs with and without VEGF treatment and absence of new bone formation in any group. Human DNA was detected in all inoculated scaffolds, but a significant decrease in cells was observed after 2 weeks with no further decrease after 12 weeks in vivo.
Under the chosen conditions, osteogenic stimulation and treatment with VEGF does not have any influence on the new bone formation and neovascularization in hMSC-seeded cancellous bone scaffolds.
用于重建大骨缺损的组织工程方法在技术上仍不成熟,尤其是在充足血供方面。因此,本研究的目的是调查成骨刺激和血管内皮生长因子(VEGF)治疗对体内接种人骨髓间充质干细胞(hMSC)的松质骨支架中新骨形成和血管生成的影响。
将hMSC接种到立方体支架上,并在干细胞培养基或成骨刺激培养基中培养。一个成骨刺激组在皮下植入无胸腺小鼠之前额外用0.8μg VEGF处理。体内2周和12周后,收获构建体和选定器官进行组织学和分子分析。
组织学分析显示,无论是否用VEGF处理,构建体的血管化情况相似,且所有组均未观察到新骨形成。在所有接种的支架中均检测到人类DNA,但体内2周后细胞数量显著减少,12周后未进一步减少。
在所选条件下,成骨刺激和VEGF治疗对接种hMSC的松质骨支架中的新骨形成和血管生成没有任何影响。